))
Poster Pearl: Dato-DXd Demonstrates Intracranial Efficacy in NSCLC
Manage episode 439677504 series 3600068
المحتوى المقدم من ReachMD. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة ReachMD أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
…
continue reading
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
9 حلقات
مشاركة
